XML 42 R29.htm IDEA: XBRL DOCUMENT v3.22.2.2
Net (Loss)/Income Per Share (Tables)
9 Months Ended
Sep. 27, 2022
Net (Loss)/Income Per Share  
Schedule of basic and diluted net income per share

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

Thirteen

​

Thirteen

​

Thirty-Nine

​

Thirty-Nine

​

​

Weeks Ended

​

Weeks Ended

​

Weeks Ended

​

Weeks Ended

​

    

September 27, 2022

    

September 28, 2021

    

September 27, 2022

    

September 28, 2021

​

​

(In thousands, except per share data)

Basic net (loss)/income per common share:

​

​

​

​

​

​

​

​

​

​

​

​

Net (loss)/income

​

$

(2,398)

​

$

32,680

​

$

46,421

​

$

70,263

Dividends on Series A preferred stock

​

 

—

​

 

—

​

 

—

​

 

(18,661)

Undistributed earnings allocated to Series A preferred stock

​

​

—

​

​

—

​

​

—

​

​

(5,804)

Net (loss)/income available to common stockholders

​

 

(2,398)

​

 

32,680

​

 

46,421

​

 

45,798

Basic weighted-average shares outstanding

​

​

49,653

​

​

50,212

​

​

50,124

​

​

46,624

Basic net (loss)/income per common share

​

$

(0.05)

​

$

0.65

​

$

0.93

​

$

0.98

​

​

​

​

​

​

​

​

​

​

​

​

​

Diluted net (loss)/income per common share:

​

​

​

​

​

​

​

​

​

​

​

​

Net (loss)/income available to common stockholders

​

​

(2,398)

​

​

32,680

​

​

46,421

​

​

45,798

Reallocation of undistributed earnings to Series A preferred stock

​

​

—

​

​

—

​

​

—

​

​

114

Net (loss)/income available to common stockholders for diluted earnings per share

​

​

(2,398)

​

​

32,680

​

​

46,421

​

​

45,912

Basic weighted-average shares outstanding

​

​

49,653

​

​

50,212

​

​

50,124

​

​

46,624

Dilutive effect of equity awards (1)

​

​

—

​

​

901

​

​

584

​

​

1,051

Diluted weighted-average shares outstanding

​

​

49,653

​

​

51,113

​

​

50,708

​

​

47,675

Diluted net (loss)/income per common share

​

$

(0.05)

​

$

0.64

​

$

0.92

​

$

0.96

(1)Shares of common stock equivalents related to outstanding stock options, restricted stock and restricted stock units of 3.3 million and 3.8 million as of September 27, 2022 and September 28, 2021, respectively, were excluded from the diluted calculation due to their anti-dilutive effect. No shares of common stock equivalents related to the Notes were included in the diluted calculation due to their anti-dilutive effect.